KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Sales: 2010-2025

Historic Return on Sales for Alnylam Pharmaceuticals (ALNY) over the last 14 years, with Sep 2025 value amounting to 0.02%.

  • Alnylam Pharmaceuticals' Return on Sales rose 18.00% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 18.00%. This contributed to the annual value of -0.12% for FY2024, which is 12.00% up from last year.
  • Alnylam Pharmaceuticals' Return on Sales amounted to 0.02% in Q3 2025, which was up 109.79% from -0.17% recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Return on Sales high stood at 0.02% for Q3 2025, and its period low was -1.53% during Q1 2021.
  • Its 3-year average for Return on Sales is -0.28%, with a median of -0.17% in 2024.
  • Its Return on Sales has fluctuated over the past 5 years, first surged by 157bps in 2021, then declined by 14bps in 2025.
  • Alnylam Pharmaceuticals' Return on Sales (Quarterly) stood at -1.01% in 2021, then dropped by 8bps to -1.09% in 2022, then surged by 85bps to -0.24% in 2023, then increased by 12bps to -0.12% in 2024, then increased by 18bps to 0.02% in 2025.
  • Its Return on Sales stands at 0.02% for Q3 2025, versus -0.17% for Q2 2025 and -0.15% for Q1 2025.